RSV Resurgence Likely in Wake of COVID-19

The impact of respiratory syncytial virus (RSV) will likely be greater in 2021 and 2022 in the United States than in previous years as a result of the ongoing COVID-19 pandemic.

Related Keywords

New York ,United States ,Florida ,Australia ,California ,Washington ,Lenore Jarvis ,Glaxosmithkline ,Yale University ,National Center ,Infectious Diseases National Institutes Of Health ,National Institute Of Allergy ,National Institutes Of Health ,Medscape Coronavirus Resource Center ,Pfizer ,George Washington University ,Roadmap For Medical Research ,Coronavirus Resource ,Zhe Zheng ,New Haven ,National Institute ,National Institutes ,Advancing Translational Science ,Pediatric News ,Pediatric Respiratory Infections ,Ediatric Respiratory Syncytial Virus Infection ,Ediatric Rsv Infection ,Ediatric Cold ,Ediatric Common Cold ,Respiratory Syncytial Virus Infection ,Inpatient Care ,Epidemic ,Coronavirus ,019 Novel Coronavirus ,019 Ncov ,Uhan Coronavirus ,Uman Coronavirus Hku1 ,Uman Coronavirus Oc43 ,Cov Oc43 ,Uman Coronavirus 229e ,Cov 229e ,Children ,Child ,Childhood ,Bed ,